186 related articles for article (PubMed ID: 34791836)
21. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Cancer Med; 2019 Nov; 8(16):6860-6870. PubMed ID: 31560165
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
[TBL] [Abstract][Full Text] [Related]
23. A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival.
Chan W; Schaffer TB; Pomerantz JL
Mol Cell Biol; 2013 Jan; 33(2):429-43. PubMed ID: 23149938
[TBL] [Abstract][Full Text] [Related]
24. The importance of functional validation after next-generation sequencing: evaluation of a novel CARD11 variant.
Lu HY; Sharma M; Biggs CM; Huang YH; Shopsowitz KE; Frosk P; Priatel JJ; Rubin TS; Turvey SE
Pediatr Allergy Immunol; 2018 Sep; 29(6):663-668. PubMed ID: 29808493
[No Abstract] [Full Text] [Related]
25. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
[TBL] [Abstract][Full Text] [Related]
26. Multiplexed Functional Assessment of Genetic Variants in CARD11.
Meitlis I; Allenspach EJ; Bauman BM; Phan IQ; Dabbah G; Schmitt EG; Camp ND; Torgerson TR; Nickerson DA; Bamshad MJ; Hagin D; Luthers CR; Stinson JR; Gray J; Lundgren I; Church JA; Butte MJ; Jordan MB; Aceves SS; Schwartz DM; Milner JD; Schuval S; Skoda-Smith S; Cooper MA; Starita LM; Rawlings DJ; Snow AL; James RG
Am J Hum Genet; 2020 Dec; 107(6):1029-1043. PubMed ID: 33202260
[TBL] [Abstract][Full Text] [Related]
27. Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
Stewart CM; Michaud L; Whiting K; Nakajima R; Nichols C; De Frank S; Hamlin PA; Matasar MJ; Gerecitano JF; Drullinsky P; Hamilton A; Straus D; Horwitz SM; Kumar A; Moskowitz CH; Moskowitz A; Zelenetz AD; Rademaker J; Salles G; Seshan V; Schöder H; Younes A; Tsui DWY; Batlevi CL
Clin Cancer Res; 2022 Jan; 28(1):45-56. PubMed ID: 34615723
[TBL] [Abstract][Full Text] [Related]
28. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.
Bruscaggin A; di Bergamo LT; Spina V; Hodkinson B; Forestieri G; Bonfiglio F; Condoluci A; Wu W; Pirosa MC; Faderl MR; Koch R; Schaffer M; Alvarez JD; Fourneau N; Gerber B; Stussi G; Zucca E; Balasubramanian S; Rossi D
Blood Adv; 2021 Nov; 5(22):4674-4685. PubMed ID: 34500472
[TBL] [Abstract][Full Text] [Related]
30. m7FLIPI and targeted sequencing in high-risk follicular lymphoma.
Sorigue M; Oliveira A; Mercadal S; Tapia G; Climent F; Perez-Roca L; Lorences I; Domingo-Domenech E; Cabezon M; Navarro JT; Gonzalez-Barca E; Zamora L; Ribera JM; Sureda A; Armengol MP; Sancho JM
Hematol Oncol; 2019 Dec; 37(5):564-568. PubMed ID: 31475375
[TBL] [Abstract][Full Text] [Related]
31. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.
Mareschal S; Dubois S; Viailly PJ; Bertrand P; Bohers E; Maingonnat C; Jaïs JP; Tesson B; Ruminy P; Peyrouze P; Copie-Bergman C; Fest T; Jo Molina T; Haioun C; Salles G; Tilly H; Lecroq T; Leroy K; Jardin F
Genes Chromosomes Cancer; 2016 Mar; 55(3):251-67. PubMed ID: 26608593
[TBL] [Abstract][Full Text] [Related]
32. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
Noy A; de Vos S; Coleman M; Martin P; Flowers CR; Thieblemont C; Morschhauser F; Collins GP; Ma S; Peles S; Smith SD; Barrientos JC; Chong E; Wu S; Cheung LW; Kwei K; Hauns B; Arango-Hisijara I; Chen R
Blood Adv; 2020 Nov; 4(22):5773-5784. PubMed ID: 33227125
[TBL] [Abstract][Full Text] [Related]
33. Screening and monitoring of the BTK
Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
[TBL] [Abstract][Full Text] [Related]
34. Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.
Bouska A; Zhang W; Gong Q; Iqbal J; Scuto A; Vose J; Ludvigsen M; Fu K; Weisenburger DD; Greiner TC; Gascoyne RD; Rosenwald A; Ott G; Campo E; Rimsza LM; Delabie J; Jaffe ES; Braziel RM; Connors JM; Wu CI; Staudt LM; D'Amore F; McKeithan TW; Chan WC
Leukemia; 2017 Jan; 31(1):83-91. PubMed ID: 27389057
[TBL] [Abstract][Full Text] [Related]
35. Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.
Snow AL; Xiao W; Stinson JR; Lu W; Chaigne-Delalande B; Zheng L; Pittaluga S; Matthews HF; Schmitz R; Jhavar S; Kuchen S; Kardava L; Wang W; Lamborn IT; Jing H; Raffeld M; Moir S; Fleisher TA; Staudt LM; Su HC; Lenardo MJ
J Exp Med; 2012 Nov; 209(12):2247-61. PubMed ID: 23129749
[TBL] [Abstract][Full Text] [Related]
36. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Morschhauser F; Tilly H; Chaidos A; McKay P; Phillips T; Assouline S; Batlevi CL; Campbell P; Ribrag V; Damaj GL; Dickinson M; Jurczak W; Kazmierczak M; Opat S; Radford J; Schmitt A; Yang J; Whalen J; Agarwal S; Adib D; Salles G
Lancet Oncol; 2020 Nov; 21(11):1433-1442. PubMed ID: 33035457
[TBL] [Abstract][Full Text] [Related]
37. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
38. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract][Full Text] [Related]
39. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
40. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
